Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 30, 2022 04:08 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE

Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at an average price of NOK 2.91 per share. Jon Olav Ødegård is CEO and primary insider...
November 11, 2022 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: THIRD QUARTER 2022 FINANCIAL REPORT

Highlights in the third quarter - HBC grew revenue by 105 % year-on-year shows strength of our business in uncertain times and during the third quarter, HBC signed contracts with new salmon...
October 17, 2022 03:24 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT

The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed...
August 30, 2022 08:25 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING

The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Tuesday 30 August 2022. All matters were approved according to the...
August 29, 2022 02:44 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: HBC’S PROGO BIOACTIVE PEPTIDES NOW IS A “NEW DIETARY INGREDIENT” (NDI) FOR THE US FDA

Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo® Bioactive Peptides. Summary Highlights...
August 26, 2022 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SECOND QUARTER & H1 2022 FINANCIAL REPORT

HBC had gross operating revenues of NOK 25.8m (31.0m) in the second quarter. For the first half of 2022 HBC had revenues of NOK 56.6m (47.9m). Cost of sales (CoGS) amounted to NOK 17.7m (21.6m) in the...
August 09, 2022 13:30 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

An Extraordinary General Meeting of Hofseth BioCare ASA will be held at the company's premises at Kipervikgata 13, 6003 Ålesund, on 30 August 2022 at 13:00 CET. Please find the notice to the General...
August 04, 2022 06:09 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED

In the annual general meeting of Hofseth BioCare ASA (the "Company") held on 29 April 2022, the general meeting resolved to carry out a private placement towards Brilliant Invest 2 AG as part of an...
July 29, 2022 02:00 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: JON OLAV ØDEGÅRD APPOINTED NEW CEO OF HBC

Following years of strong growth in Hofseth International AS ("Hofseth International") and the expected further positive development in Hofseth BioCare ASA's ("HBC") revenues and sales activities, it...
July 18, 2022 05:12 ET | Source: Hofseth Biocare ASA

Hofseth Biocare ASA: NOTIFIABLE TRANSACTION – REDELIVERY OF SHARES

Reference is made to the stock exchange notice from Hofseth BioCare ASA ("HBC" or the "Company") published on 3 July 2022 regarding the completion of a private placement raising gross proceeds of...